• Explore /
  • Poster
  • / Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).

Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).

Abstract Poster

Authors

null

Choong-kun Lee

Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

Choong-kun Lee , Hong Jae Chon , Jaekyung Cheon , Myung Ah Lee , Hyeon-Su Im , Joung-Soon Jang , Min Hwan Kim , Chan-Young Ock , Jin Won Kim , Hyung Soon Park , Myoung Joo Kang , Hye Jin Choi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT04722133

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4096)

DOI

10.1200/JCO.2022.40.16_suppl.4096

Abstract #

4096

Poster Bd #

83

Abstract Disclosures

Similar Posters

First Author: Choong-kun Lee

First Author: Aaron C. Tan

Poster

2017 Gastrointestinal Cancers Symposium

A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.

A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.

First Author: Naminatsu Takahara

First Author: Jia Fan